SAN FRANCISCO, CA—Third-year results of a “real-world” cohort
study found the antivirals entecavir and tenofovir provided comparable
efficacy for treatment-naïve patients with chronic hepatitis B and high
genetic barriers against resistance, a study concluded at IDWeek 2013.
Although HBeAg seroconversion rates at year three were significantly
higher with entecavir, the rates increased with time in both groups and
were converging, reported Dr. Fehmi Tabak of the department of infectious diseases at the Cerrahpasa Medical Faculty, Istanbul, Turkey and colleagues.